



09/674043
532 Rec'd PCT/PTC 23 OCT 2000

1103326-0642

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED OFFICE (DO/US)

PCT/SE00/01682 01 SEPTEMBER 2000 10 SEPTEMBER 1999
International Application Number International Filing Date Priority Date(s) Claimed

METHOD TO OBTAIN MICROPARTICLES

Title of Invention

SJÖBLOM, Brita

Applicant(s) for DO/US

"Express Mail" Label No. EL286880168US

Date of Deposit OCTOBER 23, 2000.

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the:
Assistant Commissioner for Patents,
Washington, D.C. 20231.

IRIS Rivera
(Type or print name of person mailing paper or fee)

[Signature]
(Signature of person mailing paper or fee)

BOX PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

To the United States Designated Office (DO/US):

- I. Accompanying this transmittal letter are certain items which are required under 35 U.S.C. 371 in order that United States National processing of the above identified International application may commence:
- (X) at the expiration of the applicable time limit under PCT Articles 22 and 39(1) according to the provisions of 35 U.S.C. 371(b).
- () as soon as possible upon receipt of this express request under 35 U.S.C. 371(f).

1. The U.S. National fee [35 U.S.C. 371(c)(1)]

a. () was previously transmitted by applicant on (date)_____.

b. (X) is submitted herewith as follows:

FOR	NO. FILED	NO. EXTRA	SMALL ENTITY			OTHER THAN		
			RATE	FEE	or	RATE	FEE	
Basic Fee	(USPTO NOT ISA OR IPEA)		////	\$500	or	////	\$1000	
Total Claims	-20 =	--	x 9 =		or	x18 =	\$	
Ind. Claims	1 - 3	--	x 40 =		or	x80 =	\$	
(X) Multiple Dependent Claim Presented			+135 =		or	+270 =	\$270	
TOTAL NATIONAL FEE			\$_____ or			<u>\$1270</u>		

- i. (X) A check in the amount of \$1270 is enclosed.
- ii. () Please charge the filing fee, multiple dependent claim fee (if applicable), excess independent claims fee (if applicable), and excess total claims fee (if applicable) to **Deposit Account No. 23-1703**.
- iii. (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to **Deposit Account No. 23-1703**. A duplicate copy of this sheet is enclosed.
- (iv) () The filing fee is not enclosed.

2. A copy of the International application as filed [35 U.S.C. 371(c)(2)]:

a. (X) is transmitted herewith.

b. () is not required as the application was filed with the United States Receiving Office.

c. () has been transmitted

- i. () by the International Bureau. Date of mailing of the application (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed.
- ii. () by applicant on (date) _____.
3. A translation of the International application into the English language [35 U.S.C. 371(c)(2)]:
- a. () is transmitted herewith.
- b. (X) is not required as the application was filed in English.
- c. () was previously transmitted by applicant on (date)_____.
4. Amendments to the claims of the International application under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. () are transmitted herewith.
- b. () have been transmitted
- i. () by the International Bureau. Date of mailing of the amendments (from form PCT/IB/308): _____.
- ii. () by applicant on (date) _____.
- c. (X) have not been transmitted as
- i. () no notification has been received that the International Searching Authority has received the Search Copy.
- ii. () the Search Copy was received by the International Searching Authority but the Search Report has not yet issued. Date of receipt of Search Copy (from form PCT/ISA/202): _____.
- iii. () applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210): _____.

- iv. ☒ the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.
5. A Translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. ☐ is transmitted herewith.
- b. ☐ is not required as the amendments were made in the English language.
- c. ☒ has not been transmitted for reasons indicated at point I.4.b. or c. above.
6. An executed declaration for patent application of the inventor [35 U.S.C. 371(c)(4)] complying with 35 U.S.C. 115:
- a. ☐ was previously submitted by applicant on (date)

- b. ☒ is submitted herewith;
and such oath or declaration
- i. ☒ is attached to the application.
- ii. ☒ identifies the application and any amendments under PCT Article 19 which were transmitted as stated in points 1.2.b. or c. and 1.4. and states that they were reviewed by the inventor as required by 37 CFR 1.70.
- c. ☐ will be submitted subsequently.

II. Concerning other documents:

1. An International Search Report or Declaration under PCT Article 17(2)(a):
- a. ☐ has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed
- b. ☐ is not required as the application was searched by the United States International Searching Authority.

c. () A copy of the International Search Report is transmitted herewith.

d. () has been submitted by applicant on (date) _____.

2. A Statement of prior art under 37 CFR 1.97 and 1.98:

a. () is transmitted herewith including copies of the references cited on the attached form PTO-1449. Also enclosed is a copy of the International-Type Search Report (PCT/ISA/201/SE), issued in the Swedish priority application.

b. () will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).

c. () was previously submitted by applicant on _____, in application serial no. _____.

3. (X) An executed Assignment is transmitted herewith for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

a. () Please charge the \$40.00 assignment recordation fee to Deposit Account No. 23-1703.

b. (X) Enclosed is a check in the amount of \$40.

4. Other document(s) or information included:

- Copy of PCT/RO/101 - The PCT Request Form; and
- Return postcard.

Respectfully submitted,

23 Oct 2000
DATE



John M. Genova
Reg. No. 32,224
Applicant's Attorney
Attorney's Direct Line - (212)-819-8832

Customer No. 007470
(212) 819-8200

enclosures

Applicant: AstraZeneca AB
S-151 85 Södertälje
Sweden

Title: METHOD TO OBTAIN MICROPARTICLES

Reference: H 2132-1

Inventors: Brita Sjöblom

METHOD TO OBTAIN MICROPARTICLES

Field of invention

The present invention provides a method of obtaining microparticles by a spray freezing technique. More specifically the present invention relates to a method by which spherical microparticles containing one or more pharmaceutically active substances can be prepared.

Background of the invention

The strategy for pharmaceutical formulation of a given drug depends on different factors. Ultimately, these factors emanate from 1) the therapeutic needs, 2) the physical chemical properties of the drug, and 3) the influence of the biological environment where the formulation will release its contents. Thus, both technical and biopharmaceutical considerations will contribute to a successful therapy.

However, improved drug administration may also be achieved by so called modified release of the drug, which has been discussed extensively in the literature, *e g R L Langer and D L Wise (Eds) "Medical Applications of Controlled Release", vols I, II (1984), CRC Press Inc, Boca Raton.*

Several approaches to achieve different types of modified release are described in the references above. Of special importance to the present invention is modified release achieved by formulating the active substance with a suitable carrier material in the form of microparticles. Such a formulation then contains multiparticulate discrete delivery units, each of which can be coated if necessary with, *e g* a suitable pH sensitive, semipermeable or other polymeric film. Several advantages can be obtained with this type of formulation compared with more conventional delivery means. Thus, the small size of the

microparticles assures a fast and predictable emptying from the stomach, which is of special importance in the presence of food. Further, the particles will spread over a larger area in the whole GI-tract compared with a conventional monolithic (single-unit) formulation. This will result in a safer therapy when the active substance has local irritating side effects. Controllable plasma levels of absorbed drug can also be obtained. The microparticle formulation will also have a longer residence time in the colon which makes 24 hrs extended release formulations possible. From a technological point of view, microparticles are more suitable for coating and handling since a technical fault during the process may be serious for single unit formulations but less so for micropellets. Also, microparticle formulations are more easily manufactured and prepared in different doses than standard tablet systems.

Prior Art

An ideal method for the preparation of microparticles where the drug is homogeneously distributed within a polymeric matrix, should be simple, reproducible, rapid and minimally dependent on the solubility characteristics of the drug. A high product yield and a high degree of retention of the active substance in the final microparticles should also be obtained.

Several different techniques are available for making microparticles (< 1 mm), e.g. spray-drying, extrusion-spheronization, spray-chilling, emulsion solvent evaporation/extraction and coating of nonpareil spheres, among others. A recent review was presented by Conti et al in STP Pharma Sci 7, 331 (1997) where the technical aspects of coacervation, spray-drying, emulsion solvent extraction, and emulsion solvent evaporation were discussed.

However, all existing techniques suffer from one or more drawbacks. Thus, many drugs are sensitive to heat and therefore will deteriorate which restricts the use of spray-drying or spray-chilling.

In extrusion spheronization and in coating of non-pareils particles it has been difficult to achieve acceptable microparticles in the size range of 50 - 400 μm . Pellets made by these methods contain significant amounts of inert excipients. This may make the pelletization of high-dose drugs by these methods a difficult task.

Finally, in emulsification solvent evaporation, an emulsion has to be made and the drug to be incorporated is preferably lipophilic, which restricts the drugs which can be used. Another drawback is the toxicity of the solvent used, usually methylene chloride, which can remain in the microparticles after drying.

However, despite the many different approaches there has not been disclosed a technique that can produce both smaller microparticles but also particles of more uniform size. It is important to avoid, e g segregation and dose variation during further processing into capsules or tablets. Further, the existing techniques do not incorporate several desirable aspects such as the possibility to produce spherical microparticles of different size ranges that are homogeneous, have a high drug content and sufficient mechanical strength (to e g withstand coating processes) into one single technique.

A spray-freezing technique has been used for the processing and granulation of ceramic materials to achieve homogeneous distribution of additives within granules to be compacted. For the processing of slurries containing silicon-nitride, sintering additives and a binder, spherical free-flowing granules have been prepared by spray-freezing and subsequent freeze-drying. The homogeneity of the slurry was retained in the granules and thus in the final sintered product (Nyberg et al, Euro-Ceramics II 1, 447 (1993)).

Suspensions of silicon carbide and additives were processed in this way to give granules for compaction (US Patent 4,526,734). The increased homogeneity compared with traditional granulation techniques resulted in better mechanical properties of a whisker reinforced ceramic (EP 0 584 051). The process is also feasible for making homogeneous powder blends for ceramic superconductors (Japanese unexamined patent application no. 59-102433).

Normally pharmaceutical materials are lyophilized by freeze-drying in a bulk process in which the solution/suspension to be freeze-dried is placed in vials or on trays in a freeze-drier, where freezing and subsequent sublimation of the dry solvent take place. The dried product is a powder cake.

The rapid freezing provided by spray-freezing ensures that no concentration gradients exist in the resulting frozen particles and degradation of biological material is prevented. This approach has been used to achieve precise metering and dispensing (M J Akers and D J Schmidt, BioPharm 28, (April 1997)); where the frozen particles were in the form of large lumps of size 1-9 mm. Freezing of droplets in a moving bath of Freon 12 (-20°C), which medium conflicts with environmental demands, has been used to obtain porous, free-flowing, spherical granules with rapid dissolution (US patent 3,932,943); as well as making homogenous granules for tableting with precise dosing (US Patent 3,721,725).

A process for preparing foamed bioabsorbable polymer particles for surgical use was presented in US Patent 5,102,983. Here, however, the porosity was very large, and the pore sizes in the range of 4 - 10 μ m, the dry content of the solution being sprayed being 1 - 20 wt%.

US Patent 5,019,400, disclosed the use of a mixture of a biologically active material, a polymer, and a solvent which was sprayed into a non-solvent cooling medium that froze the droplets with subsequent extraction of the solvent in the droplets during heating. The particles were finally dried in a vacuum-drier. The microparticles formed were porous, and contained 0.01 - 50 % of the active substance. The dry content of the solution sprayed was 6 wt%. This process is not entirely satisfactory since it is an advantage to have one single drying step after freezing and also a higher active substance content than 50 wt% in order to make high dose materials.

US Patent 5,405,616 discloses a method of forming droplets by forcing a suspension/solution/emulsion through calibrated jets. The droplets then fall into liquid nitrogen. Due to low shear forces the size of the pellets formed is large; 0.2 - 12 mm, which would then give a less safe dosability than if smaller particles could have been achieved. The smallest particles achieved were 0.8 - 1 mm. Further, to achieve low friability pellets, the drying step after freeze-drying was performed by thawing the pellets before conventional vacuum drying. To achieve these low friability pellets the matrix former is restricted to materials that during thawing will form a gel. The particles obtained contain no more than 33 wt% of the active substance.

To the skilled person particle production utilizing the technique described in US 5,405,616 appears to be quite a slow process and not suitable for large scale industrial pharmaceutical production.

Object of the invention

An object of the present invention is to provide a method for the production of microparticles. More specifically, the method is for the production of homogeneous microparticles which does not have the drawbacks of the methods discussed above, e.g. methods that rely on heat or multiple solvents for drug dissolution, but instead puts no restrictions on the drug to be incorporated. A further object is to provide a method for the production of microparticles with controllable amounts of incorporated drug in a high-yield process. Also, the invention provides a method to produce homogeneous microparticles with an incorporated drug that have low friability so that they for instance can withstand coating processes. A further object of the invention is to provide a method to produce microparticles that have easily controllable density and strength. A further object is to obtain microparticles with a high content of active substance.

Disclosure of the invention

It has now been found that free-flowing, homogeneous microparticles having low friability can be obtained by spray-freezing a suspension, solution or emulsion of a pharmaceutically active substance with subsequent freeze-drying of the frozen microparticles. The microparticles are preferably spherical in shape. The porosity of the microparticles obtained is controlled in the process by the dry content of the suspension, solution or emulsion. Apart from the porosity, the brittleness of the microparticles is controlled by the amount of polymer binder included in the suspension, solution or emulsion. In order to obtain low friability particles the dry content of the suspension or solution or emulsion should be high.

Generally the following conditions are applicable to obtain low friability microparticles according to the method of the invention;

Low friability microparticles, that can for instance withstand coating with a polymeric film, are achieved when the suspension, solution or emulsion has a dry volume content of at least 15 vol%, preferably up to 60 vol %, and a polymer binder content of at least 5 weight %, preferably 10 weight % or more, and more preferably 15 weight % or more (based upon dry content). A high total pharmaceutically active substance content can be obtained by using the present invention, such as up to 95 weight % or preferably 90 weight % (based upon dry content). The median pore size of the microparticles obtained being preferably a maximum of 1.0 μm . Dry content and dry volume content are weight % and volume %, respectively, of dry material in the suspension/solution/emulsion (dry/(dry + liquid)), wherein the dry material is pharmaceutically active substance + polymer.

According to the present invention homogenous low friability microparticles can be obtained when the dry content is from 15 to 60 vol % and the polymer binder content is 5 weight % or more giving dry microparticles with a relative density of 15 to 60 % (a

porosity of 85 down to 40 vol %). [Relative density: weight of freeze-dried material/volume of freeze-dried material/theoretical density of dry material].

The content of the pharmaceutically active substance calculated on the weight of the dried microparticles may be from 60 to 95 weight %, preferably from 75 to 90 weight %.

The dry content of the liquid medium is defined as the residue after drying at 110°C for 2 hours, divided by the total amount before drying. The dry content can be expressed either as weight percent or, preferably, as volume percent.

The success in obtaining low porous microparticles and thus low friable microparticles depends on the volume fraction of dry material and the amount of polymer binder. The dry content of a suspension/solution/emulsion should thus preferably be expressed as a volume fraction although this cannot always be calculated.

The microparticles may be obtained by spraying a homogeneous suspension, solution or emulsion of the active substance(s) through an atomizer into a vessel with a cold medium with a temperature well below that of the freezing point of the liquid in the droplets. Frozen droplets will then form instantaneously. The structure of the suspension, solution or emulsion is retained in the droplets providing a homogeneous distribution of the substances within the droplets. The frozen liquid is then sublimated by freeze-drying of the frozen droplets where the structure of the droplets is retained due to lack of migration of substances during drying.

The following general steps of the procedure are further exemplified in the Experimental Section below :

a) Preparation of a medium for atomizing. The medium is a suspension, a solution or an emulsion of the active substance. A suspension may be prepared by dissolving or dispersing a polymer in a liquid (as defined below), and then adding fine particles of the

active substance. A further dispersing agent (typically in an amount of less than 20 %
(w/w) of the polymer amount) might also be included to facilitate the dispersion of the
active substance. The polymer might then act as a binder between the fine active substance
particles in the microparticles and can be either a water soluble or a non-water soluble
polymer, according to definitions below.

b) Atomizing of the suspension/solution/emulsion into droplets. The suspension, solution
or emulsion is fed by e.g. a peristaltic pump through a nozzle that could be a pneumatic
nozzle, an ultrasonic nozzle, a rotary atomizer or a pressurized nozzle. A typical size
distribution of spheres produced by this process can range from 1000 μm down to 10 μm .

c) Freezing of the formed droplets: The atomizer is situated above the cold medium in a
cylindrical vessel. If the cold medium is a liquified gas the droplets in the spray formed by
the nozzle hit the cold boiling gas before hitting the cold medium that is stirred to get a
better wetting of the droplets. Instant freezing takes place and the structure of the
homogeneous suspension is retained within the frozen microparticles.

d) Sublimation of the frozen liquid within the droplets: The frozen droplets are transferred
from the cold medium to a freeze-drier to sublimate the frozen liquid. This step takes place
without any shrinkage of the droplets or migration of excipients (e g polymers) and thus
the structure of the suspension/solution/emulsion is retained within the dry microparticles.

The polymer or dispersing agent used for the formulation may be a dry polymer that is
partly or fully soluble in the liquid. The polymer or dispersing agent used might also be a
dispersion of polymer particles (e g a latex).

The polymer or dispersing agent could be but are not limited to the excipients listed below.

- *cellulose derivatives*, like ethylcellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, ethyl hydroxyethyl cellulose, carboxymethyl cellulose, cellulose acetate butyrate, cellulose acetate phthalate, methylcellulose, etc

5 - *other polysaccharides*, like alginate; xanthan; carrageenan; scleroglucan; pullulan; dextran; hyaluronic acid; chitin; chitosan; starch; etc

- *other natural polymers*, like proteins (e g albumin, gelatin, etc); natural rubber ; *gum arabic*; etc

10

- *synthetic polymers*, like acrylates (e g polymethacrylate, poly(hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(hydroxy ethyl methacrylate - co methyl methacrylate), Carbopol® 934, etc); polyamides (e g polyacrylamide, poly(methylene bisacrylamide), etc); polyanhydrides (e g poly(bis carboxyphenoxy)methane, etc); PEO-
15 PPO block-co-polymers (e g poloxamers, etc); polyvinyl chloride; polyvinyl pyrrolidone; polyvinyl acetate; polyvinyl alcohol; polyethylene, polyethylene glycols and co-polymers thereof; polyethylene oxides and co-polymers thereof; polypropylene and co-polymers thereof; polystyrene; polyesters (e.g. poly(lactic acid), poly(glycolic acid), poly(caprolactone), etc, and co-polymers thereof, and poly(ortho esters), and co-polymers
20 thereof); polycarbonate; cellophane; silicones (e.g. poly (dimethylsiloxane), etc); polyurethanes; synthetic rubbers (e.g. styrene butadiene rubber, isopropene rubber, etc); etc

- *surfactants*, e.g. anionic, like sulphated fatty alcohols (e g sodium dodecyl sulphate),
25 sulphated polyoxyethylated alcohols or sulphated oils, etc; cationic, like quaternary ammonium and pyridinium cationic surfactants, etc; non-ionic, like polysorbates (e.g. Tween), sorbitan esters (e.g. Span), polyoxyethylated linear fatty alcohols (e.g. Brij), polyoxyethylated castor oil (e g Cremophor), polyoxyethylated stearic acid (e g Myrj), etc.

00674043-10200

- *other substances*, like shellacs; waxes (e.g. carnauba wax, beeswax, glycowax, castor wax, etc); nylon; stearates (e.g. glycerol palmitostearate, glyceryl monostearate, glyceryl tristearate, stearyl alcohol, etc); lipids (e.g. glycerides, phospholipids, etc); paraffin; lignosulphonates; etc.

Also, combinations of these excipients are possible.

The excipients mentioned above can be toughened by introducing a plasticizer. The plasticizer can be but is not limited to the plasticizers mentioned below.

- glycerin, polyethylene glycol, propylene glycol, triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, sorbitol, triacetin, etc

Also, combinations of these plasticizers are possible.

The liquid used for the preparation of the suspension/solution/emulsion, can be a solvent for the excipients listed above and encompass, e.g. water or organic solvents with freezing points well above the freezing point of the medium used for freezing as exemplified below. Liquids, alone or a mixture of, suitable to make a suspension/solution/emulsion of the active substance, can then be, but are not limited to:

- water (melting point (mp) 0°C), tertiary butyl alcohol (mp 25.5 °C), cyclohexane (mp +6°C), methylene chloride (mp -95.1 °C), acetone (mp -95.3 °C), methanol (mp -94 °C), ethanol (mp -117 °C), etc;

The cold medium can typically be a liquified gas, e.g. liquid nitrogen (boiling point -196°C), liquid argon (boiling point -186 °C), liquid oxygen (boiling point -183 °C), or a cooled solvent well below the freezing point of the liquid in the suspension.

The mechanical strength of the microparticles is important for determining whether they will withstand processing with a polymer coating in a fluid bed.

Examining the microparticles with a microscope before and after the fluidization in a fluid bed will give an indication of their mechanical strength.

5 To achieve a relative measurement of mechanical strength the pressure where microparticles started to deform was evaluated. Microparticles within a certain size range (sieve fraction) were placed as a monolayer onto the surface of a probe with a certain area. Different loads (forces) were applied to the layer of microparticles for one minute.

10 Examination of the monolayer of microparticles before and after loading was made in a Scanning Electron Microscope to see at what load the microparticles started to deform. The pressure at which the microparticles started to deform was then calculated.

Pharmaceutically active substances suitable to form microparticles of this invention can be
15 but are not limited to peptides, proteins, low molecular organic substances, pro-drugs, antigens, hormones.

Thus, a microparticle according to the present invention comprises one (or several) pharmaceutically active substances with one or several additional non-active substances,
20 which are dispersed within the microsphere.

Uncoated particles can be retrieved as they are easily dissolved when they are immersed into a liquid due to their porous structure.

25 The microparticles obtained can be coated with a polymer to achieve either a time-controlled release, a site-controlled release or a pH-dependent release. Suitable polymers for coating can be, but are not limited to, the same type of polymers as listed above.

The coated microparticles can be put into capsules or incorporated into a tablet compressed
30 by methods known by those skilled in the art.

The formulations produced based on the microparticles, coated or uncoated, can be given by different administration routes, such as, but not limited to, the oral, the parenteral, the nasal, the pulmonary, the rectal, the tonsillar, the buccal, the intraocular, the vaginal etc, administration routes. The preferred administrations are by the oral, nasal, pulmonary and rectal routes.

Working examples

The following examples illustrate different aspects of the invention.

The size distribution of the obtained microparticles was measured by sieving. By mercury porosimetry measurements the bulk-density and pore-size distributions were determined. To determine the median pore size the pressure range for mercury intrusion corresponded to pore sizes between 0.0005 μm and 10 μm .

By subjecting a monolayer of the microparticles to compaction forces their relative strength was measured.

EXAMPLE 1: Preparation of microparticles with a high loading of dry content that withstand coating in a fluidized bed

A suspension containing talc powder was made according to the composition below;

Talc powder (1-2 μm)	90 g
Talc powder (5 - 80 μm)	210 g
HPMC, 6 cps	80 g
Tween 80 (polysorbate 80)	6 g
Purified water	750 g

Weight percent of dry content in suspension: 34 (19.2 vol%)

First, polysorbate 80 was mixed with the water. The HPMC was then added and dissolved during stirring with subsequent addition of the substance. The suspension was then
5 deagglomerated by high-shear mixing. The deagglomerated suspension was fed through a pneumatic nozzle with a diameter of 1.0 mm at a speed of about 15 ml/min. The pressure of the atomizer was 1 bar. The spray formed first hit the cold gas above the liquid in a vessel filled with liquid nitrogen that was stirred to get a better wetting and instantaneous freezing of the droplets. The frozen droplets have a higher density than liquid nitrogen
10 which make them sink to the bottom of the vessel. The frozen droplets/microparticles were then placed in a conventional freeze-drier with a shelf-temperature of -20°C. The primary drying was performed stepwise at -20°C to 0°C at 0.1 mbar. The dry microparticles were free-flowing and spherical. Scanning Electron Microscopy showed a homogeneous distribution of the talc powder with pores (0.1 - 2 µm) in between. The bulk density,
15 median pore size and mechanical strength was measured and the results are shown in table 2.

Compaction measurements showed that the microparticles obtained had a low friability (high mechanical strength).

20 Fluidization of the microparticles in Example 1 in a fluidized bed showed by microscopy that the microparticles did not break down. These microparticles started to deform at a pressure of 94 kPa (sieve fraction: 450-630 µm). Final coating with a polymer in a fluidized bed proved that the microparticles could be successfully coated.

25 EXAMPLE 2: Coating of microparticles with a polymeric film

The microparticles from Example 1 were easily handled without falling apart and tough enough to be successfully coated. A fraction of 20 g of the microspheres, 150 - 300 µm in

Characterization of pellets obtained in example 1.

Table 1. Size distribution. Sieving (weight fraction%)

Fraction	Example 1
< 100 μm	1
100 - 150 μm	2
150 - 300 μm	22
300 - 450 μm	32
450 - 630 μm	26
630 - 800 μm	12
800 - 1000 μm	4

5

Table 2. Characterization of microparticles

Example no.	Dry content (vol%)	Binder (wt%) based on dry content	Mercury porosity measurements		Mechanical strength	
			Bulk density (g/cm ³)	Pore median size (μm) (measured range: 0.0005- 10 μm)	Kpa	Fraction
1	19.2	21	0.47	0.8	94	450 - 630 μm

CLAIMS

1. A method of preparing homogeneous microparticles containing a pharmaceutically active substance by use of a spray freezing technique which method comprises

5 - atomizing into droplets a liquid medium having a minimum dry content of 15% by volume and comprising

a) a pharmaceutically active substance,

b) a polymer selected from the group consisting of water soluble polymers and non-water soluble polymers, said polymer being present in an amount of at least

10 5 per cent by weight based upon the dry content of the medium,

c) a liquid in which the pharmaceutically active substance and polymer are suspended, dissolved or emulsified, and

d) optionally a dispersing agent, selected from the group consisting of polymers, surfactants, other substances and mixtures thereof,

15 - freezing the formed droplets and

- sublimating the frozen liquid of the droplets to obtain dry, homogeneous microparticles.

2. A method according to claim 1, wherein the polymer of the liquid medium constitutes
20 10 weight % or more of the dry content.

3. A method according to claim 1, wherein the polymer of the liquid medium constitutes 15 weight % or more of the dry content.

25 4. A method according to claim 1 wherein the dry content of the liquid medium is from 15 to 60 vol %.

5. A method according to claim 1, wherein the dry volume content of the liquid medium is from 15 to 60 vol % and gives dry microparticles with a relative density of 15 to 60 %.

6. A method according to claim 1, wherein the dry volume content of the liquid medium is from 15 to 60 vol % and gives dry microparticles with a porosity of 85 down to 40 vol %.

5 7. A method according to claim 1 wherein the liquid medium to be spray-freezed is a suspension.

8. A method according to claim 1 wherein the liquid medium to be spray-freezed is a solution.

10

9. A method according to claim 1 wherein the liquid medium to be spray-freezed is an emulsion.

15

10. A method according to any of the preceding claims wherein the content of the pharmaceutically active substance is from 60 to 95 weight %, preferably 75 to 90 weight %, of the weight of the dried microparticles.

20

11. A method according to any of the preceding claims wherein the dry content of the medium is from 15 to 60 vol% and with the content of the pharmaceutically active substance being from 60 to 95 weight % of the dried microparticles.

25

12. A method according to any of the preceding claims wherein the polymer is selected from the group consisting of a cellulose derivative, a polysaccharide, a natural polymer, a synthetic polymer, a surfactant and mixtures thereof.

13. A method according to any of the preceding claims wherein the dispersing agent is selected from the group consisting of polymers, surfactants, other substances and mixtures thereof.

15. A method according to any of the preceding claims wherein the cold medium is selected from the group consisting of liquid nitrogen, liquid argon, liquid oxygen or a cooled solvent well below the freezing point of the liquid in the suspension.

17. A method according to any of the preceding claims wherein the size distribution of the prepared microparticles are in the range from 10 to 1000 μm .

19. The microparticles according to claim 18 further comprising a polymeric film coating.

20 20. A method of preparing homogenous microparticles containing a pharmaceutically active substance, the particles being coated with a polymer film coating, which method comprises a method as claimed in any one of claims 1-17 followed by coating the microparticles with a polymeric film coating.

ABSTRACT

A method for the preparation of homogeneous microparticles containing a

pharmaceutically active substance by a spray freezing technique wherein the medium to be atomized into droplets has a high dry content and comprises besides the active substance a polymer and a liquid (in which the polymer may be soluble) in which the active substance and polymer are suspended, dissolved or emulsified.

[illegible]

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHOD TO OBTAIN MICROPARTICLES the specification of which is attached hereto unless the following box is checked:

☒ was filed on 01.09.2000 as United States Application Number or PCT International Application Number PCT/SE00/01682 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

9903236-9
(Number)

Sweden
(Country)

10 September 1999
(Day/Month/Year Filed)



(Number)

(Country)

(Day(Month/Year Filed)



I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)	(Filing Date)	(Status -- patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Nels T. Lippert, Reg. No. 25,888; Dimitrios Drivas, Reg. No. 32,248; Robert B. Smith, Reg. No. 28,538; David Bender, Reg. No. 35,445; John M. Genova, Reg. No. 32,224; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Cecilia O'Brien Lofers, Reg. No. 33,434; Leslie Morioka, Reg. No. 40,304; John Scheibeler, Reg. No. 35,346; Thelma A. Chen Cleland, Reg. No. 40,948; Jean E. Shimotake, Reg. No. 36,273; Jeff Oelke, Reg. No. 37,409; Thomas E. Malone, Reg. No. 40,078; and Douglas R. Nemec, Reg. No. 41,249, all of the firm of WHITE & CASE Limited Liability Partnership, with offices at 1155 Avenue of the Americas, New York, New York 10036.
Address all telephone calls to _____ at telephone number (212) 819-8200
Address all correspondence to WHITE & CASE LLP

Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor
(given name, family name)

Brita Sjöblom

First inventor's signature

Brita Sjöblom

Date:

4 October 2000

Residence Address

Hovås, Sweden

SEX

Citizenship

Swedish

Post Office Address

AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden